Abstract 3073
Background
Management of Ca treatment-related symptoms is an important safety issue. The value of nursing in symptom management is critical and becoming increasingly so as the treatment becomes more remarkably complex.
Methods
Qualitative research Descriptive case study Describe the problems of a 28year old dx with Hodgkin’s Disease.
Results
Chemotherapy Day Hospital (CDH) was the 1st contact with the oncology reality Focus: familiarization with a hostil atmosphere develop links between patient-nurses change of routines impact on ADL management of CT’s effects therapeutic regimen increase one’s resilience and hope while in treatment reduce long-term complications of the Ca tips to promote comfort: minimize suffering assisting patient navigation in the care continuum Relapse after 6 months New CT treatment (inpatient setting) Anxiety attacks due to the adaptation/awareness of his new condition Focus: management of bad news and CT’s side effects requested collaboration to the nurse of the CDH in the adaptation of strategies of adhesion to the new CT/hospitalization hospital routines adapted to his habits self care promotion psychological support articulation between services communication among nurses - promote the continuity of care New relapse Began immunotherapy: hospitalized after pulmonar toxicity In this scope he performed a bronchoscopy No curative therapy indication Due to tiredness/dyspnea a personalized respiratory rehabilitation plan was developed by a nurse: breathing optimization energy conservation techniques teaching positions of rest/relaxation In the end-of-life were adopted non-pharmacological strategies: relief of dyspnea (guidelines of the nurse of the bronchoscopy unit) positioning massage distraction techniques his mother was allowed to spend the night with him D/C was possible to fulfill one of his desires After a month he was admitted (neurological changes) and passed away.
Conclusions
During the treatment period of the disease the patient went through 3 distinctive services where it was necessary to have an individualized/specialized approach as well as an articulation/communication among the nurses in order to guarantee an effectively management of symptoms and the quality/safety of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract